微芯生物
(688321)
| 流通市值：120.43亿 | | | 总市值：130.80亿 |
| 流通股本：4.08亿 | | | 总股本：4.43亿 |
| 报告期 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 347,573,821.36 | 451,158,735.59 | 490,156,626.11 | 369,285,450.12 |
| 交易性金融资产 | 295,295,267.5 | 185,252,525.49 | 77,007,272.22 | 133,158,207.65 |
| 应收票据及应收账款 | 298,798,849.65 | 286,752,495.8 | 207,011,418.47 | 139,251,135.31 |
| 其中：应收票据 | 11,808,591.16 | 17,624,290.28 | - | - |
| 应收账款 | 286,990,258.49 | 269,128,205.52 | 207,011,418.47 | 139,251,135.31 |
| 预付款项 | 7,881,433.1 | 11,530,439.12 | 6,462,135.5 | 11,653,496.31 |
| 其他应收款合计 | 7,508,024.85 | 9,008,655.47 | 7,916,635.41 | 8,470,203.04 |
| 存货 | 57,682,273.4 | 53,671,739.21 | 54,616,769.12 | 50,753,968.26 |
| 合同资产 | 990,491.78 | 1,643,457.57 | 1,008,277.16 | 1,198,161.12 |
| 其他流动资产 | 164,658,513.07 | 339,506,438.9 | 402,220,256.83 | 421,057,000.91 |
| 流动资产合计 | 1,180,388,674.71 | 1,338,524,487.15 | 1,246,399,390.82 | 1,134,827,622.72 |
| 非流动资产: | | | | |
| 长期股权投资 | 228,857,081.85 | 232,641,221.15 | 238,836,734.35 | 240,619,976.13 |
| 投资性房地产 | 116,158,482.42 | 117,037,732.98 | 117,916,983.54 | 118,796,234.09 |
| 固定资产 | 933,724,460.98 | 777,738,525.17 | 780,977,662.48 | 778,407,482.79 |
| 在建工程 | 351,402,757.6 | 469,911,875.95 | 371,537,304.91 | 372,546,524.6 |
| 使用权资产 | 7,990,924.53 | 8,806,222.65 | 9,284,375.8 | 10,181,493.84 |
| 无形资产 | 417,816,962.93 | 425,527,277.99 | 432,985,626 | 440,507,935.96 |
| 开发支出 | 239,911,313.08 | 218,082,151.06 | 193,008,289.66 | 172,362,595.26 |
| 长期待摊费用 | 15,725,251.36 | 16,340,254.57 | 16,222,946.88 | 15,433,110.41 |
| 递延所得税资产 | 2,900,719.86 | 1,623,321.86 | 1,526,958.65 | 1,466,300.91 |
| 其他非流动资产 | 155,619,766.51 | 26,959,757.38 | 26,106,920.03 | 26,553,851.66 |
| 非流动资产合计 | 2,470,107,721.12 | 2,294,668,340.76 | 2,188,403,802.3 | 2,176,875,505.65 |
| 资产总计 | 3,650,496,395.83 | 3,633,192,827.91 | 3,434,803,193.12 | 3,311,703,128.37 |
| 流动负债: | | | | |
| 短期借款 | 159,797,984.22 | 168,773,823.8 | 135,041,361.11 | 135,035,416.67 |
| 应付票据及应付账款 | 3,781,024 | 4,315,800.07 | 5,635,887.98 | 1,372,758.86 |
| 应付账款 | 3,781,024 | 4,315,800.07 | 5,635,887.98 | 1,372,758.86 |
| 预收款项 | 1,550,092.93 | 2,030,259.07 | 2,574,209.95 | 2,600,542.73 |
| 合同负债 | 151,223.84 | 268,601.9 | 483,789.36 | 2,575,906.84 |
| 应付职工薪酬 | 46,948,238.97 | 36,958,474.23 | 29,006,213.31 | 29,425,157.6 |
| 应交税费 | 14,559,810.28 | 15,233,406.03 | 11,271,706.77 | 9,356,741.5 |
| 其他应付款合计 | 269,471,896.91 | 231,141,801.15 | 169,425,043.95 | 171,030,853.76 |
| 一年内到期的非流动负债 | 347,642,182.16 | 257,316,285.33 | 297,067,516.72 | 130,045,902.57 |
| 流动负债合计 | 843,902,453.31 | 716,038,451.58 | 650,505,729.15 | 481,443,280.53 |
| 非流动负债: | | | | |
| 长期借款 | 560,240,879.94 | 649,062,416.61 | 565,477,783.28 | 688,939,319.95 |
| 应付债券 | 475,198,952.19 | 468,853,801.77 | 458,505,892.44 | 450,158,055.21 |
| 租赁负债 | 4,886,370.95 | 5,239,027.14 | 5,990,250.8 | 6,924,233.78 |
| 预计负债 | 162,883.56 | 253.56 | 606.88 | 1,596.96 |
| 递延收益 | 101,403,753.62 | 99,930,534.57 | 102,417,613.4 | 82,950,436.98 |
| 递延所得税负债 | 38,877,038.24 | 38,184,431.62 | 37,151,559.54 | 39,423,807.2 |
| 非流动负债合计 | 1,180,769,878.5 | 1,261,270,465.27 | 1,169,543,706.34 | 1,268,397,450.08 |
| 负债合计 | 2,024,672,331.81 | 1,977,308,916.85 | 1,820,049,435.49 | 1,749,840,730.61 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 407,807,559 | 407,807,559 | 407,796,477 | 407,796,477 |
| 其他权益工具 | 123,697,115.47 | 123,697,158.94 | 123,766,533.48 | 123,766,533.48 |
| 资本公积 | 1,022,994,358.06 | 1,017,790,369.76 | 1,017,470,006.96 | 1,013,197,876.53 |
| 减:库存股 | 14,999,140.22 | - | - | - |
| 其他综合收益 | 7,103,078.4 | 7,559,377.76 | 7,866,580.61 | 7,994,252.71 |
| 盈余公积 | 33,456,588.43 | 25,250,701.46 | 25,250,701.46 | 25,250,701.46 |
| 未分配利润 | 45,764,504.88 | 73,778,744.14 | 32,603,458.12 | -16,143,443.42 |
| 归属于母公司股东权益合计 | 1,625,824,064.02 | 1,655,883,911.06 | 1,614,753,757.63 | 1,561,862,397.76 |
| 股东权益合计 | 1,625,824,064.02 | 1,655,883,911.06 | 1,614,753,757.63 | 1,561,862,397.76 |
| 负债和股东权益合计 | 3,650,496,395.83 | 3,633,192,827.91 | 3,434,803,193.12 | 3,311,703,128.37 |
| 公告日期 | 2026-03-31 | 2025-10-31 | 2025-08-26 | 2025-04-26 |
| 审计意见(境内) | 标准无保留意见 | | | |